Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...

Hypersensitivity Reactions: Cytolytic Reactions

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Nephrotic Syndrome II : Assessment and Medical Management

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differential distribution of HLA-A, HLA-B, and HLA-DRB1 allele groups in Iranian pediatric and adult patients with acute lymphoblastic Leukemia: A Case-Control study.

Human immunology·2026

Same author

Homozygous C1qA Deficiency Presenting as Early-Onset Systemic Lupus Erythematosus: A Case Report With a Literature Review.

Case reports in immunology·2026

Same author

Interactions of dual antiplatelet and anticoagulant with C1q and FH regulate complement activation by injured cells.

Blood vessels, thrombosis & hemostasis·2026

Same author

Incidence, risk factors, and mortality impact of chronic kidney disease in middle-aged Finns: a 22-year population-based cohort study.

BMC nephrology·2026

Same author

Baseline malaria burden and pyrethroid resistance in Muheza, Tanzania informing a cluster randomized trial of the 3D window screens.

Scientific reports·2026

Same author

Impact of hepatitis C therapy on urinary outcomes and renal function: a prospective real-world cohort study of early kidney changes.

BMC nephrology·2026

Search research articles

Related Experiment Video

Updated: Feb 16, 2026

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Published on: June 13, 2025

Atypical hemolytic-uremic syndrome.

Kati Kaartinen, Leena Martola, Seppo Meri

Duodecim; Laaketieteellinen Aikakauskirja

|December 16, 2017

Summary

Atypical hemolytic-uremic syndrome (aHUS) is a rare condition caused by complement system dysregulation. Eculizumab, a complement inhibitor, has transformed treatment for patients with this serious thrombotic microangiopathy.

Area of Science:

Nephrology
Hematology
Immunology

Background:

Atypical hemolytic-uremic syndrome (aHUS) is a rare thrombotic microangiopathy.
It stems from dysregulation of the complement alternative pathway, targeting endothelial and blood cells.
Causes include genetic mutations (e.g., Factor H) or autoantibodies against complement regulators.

Purpose of the Study:

To summarize the pathophysiology and clinical presentation of aHUS.
To highlight the impact of novel therapeutic interventions.

Main Methods:

Review of existing literature on aHUS.
Analysis of clinical data regarding disease progression and treatment outcomes.

Main Results:

More Related Videos

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

Related Experiment Videos

Last Updated: Feb 16, 2026

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Development of Human Renal Tubular Epithelial Cell Primary Cultures in Monolayers and Three-Dimensional Conditions

Published on: June 13, 2025

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

Published on: April 5, 2019

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Published on: June 2, 2022

aHUS involves aberrant complement activation, leading to microangiopathic hemolysis and acute kidney injury.

Other organ involvement can occur to varying degrees.

Eculizumab, a terminal complement inhibitor, has shown significant efficacy.

Conclusions:

Understanding complement dysregulation is key to aHUS pathogenesis.
Eculizumab represents a breakthrough in managing aHUS, improving patient outcomes.